Anika Therapeutics Inc (ANIK)

Price$14.48

Value ScoreC

Growth ScoreF

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)38.63%

Price vs S&P 500 (4W)-1.95%

VGM Score47.38

Market Capitalization$192.67M

All Metrics

P/CF (Annual)17.22x

Book Value / Share (Quarterly)$10.02

P/TBV (Annual)0.98x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-10.28%

Cash Flow / Share (Quarterly)$0.08

Price vs S&P 500 (YTD)42.52%

Gross Margin (TTM)58.59%

Net Profit Margin (TTM)-9.52%

EPS (TTM)$-0.79

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-0.79

Revenue Growth (5Y)-2.87%

EPS (Annual)$-0.76

ROI (Annual)-7.58%

Gross Margin (Annual)56.56%

Net Profit Margin (5Y Avg)-22.61%

Cash / Share (Quarterly)$3.07

Revenue Growth QoQ (YoY)13.16%

ROA (Last FY)-5.72%

Revenue Growth TTM (YoY)-15.41%

EBITD / Share (TTM)$-0.48

ROE (5Y Avg)-17.39%

Operating Margin (TTM)-10.54%

Cash Flow / Share (Annual)$0.31

P/B Ratio1.44x

P/B Ratio (Quarterly)1.45x

Net Income / Employee (Annual)$-46,300

EV / Revenue (TTM)1.30x

Net Interest Coverage (TTM)13.00x

ROA (TTM)-5.93%

EV / EBITDA (TTM)61.90x

EPS Incl Extra (Annual)$-0.76

Current Ratio (Annual)4.72x

Quick Ratio (Quarterly)3.19x

3-Month Avg Trading Volume0.13M

52-Week Price Return29.40%

EV / Free Cash Flow (Annual)34.77x

Revenue / Employee (TTM)$494,700

Tangible BV / Share (Quarterly)$9.90

P/S Ratio (Annual)1.71x

Asset Turnover (Annual)0.59x

52-Week High$16.24

Operating Margin (5Y Avg)-4.84%

EPS Excl Extra (Annual)$-0.76

CapEx CAGR (5Y)33.17%

Tangible BV CAGR (5Y)-4.78%

26-Week Price Return46.56%

Quick Ratio (Annual)3.71x

13-Week Price Return1.61%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.46x

Enterprise Value$151.65M

Revenue / Share Growth (5Y)-3.06%

Asset Turnover (TTM)0.62x

Book Value / Share Growth (5Y)-11.52%

Revenue / Employee (Annual)$480,100

Inventory Turnover (Annual)2.30x

Pretax Margin (Annual)-8.25%

Cash / Share (Annual)$4.14

3-Month Return Std Dev63.01%

Gross Margin (5Y Avg)57.20%

Net Income / Employee (TTM)$-47,100

EBITDA CAGR (5Y)-46.37%

ROE (Last FY)-7.58%

Net Interest Coverage (Annual)-7.33x

EPS Basic Excl Extra (Annual)$-0.76

P/FCF (TTM)21.47x

Receivables Turnover (TTM)4.87x

EV / Free Cash Flow (TTM)145.95x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.79

Receivables Turnover (Annual)4.77x

ROI (TTM)-7.74%

P/S Ratio (TTM)1.66x

Pretax Margin (5Y Avg)-3.80%

Revenue / Share (Annual)$7.87

Tangible BV / Share (Annual)$10.21

Forward P/E49.19x

Free OCF CAGR (5Y)-17.54%

Price vs S&P 500 (52W)5.04%

Year-to-Date Return50.68%

5-Day Price Return-1.03%

EPS Normalized (Annual)$-0.76

ROA (5Y Avg)-13.43%

Net Profit Margin (Annual)-9.64%

Month-to-Date Return-0.34%

Cash Flow / Share (TTM)$-0.69

EBITD / Share (Annual)$-0.40

Operating Margin (Annual)-9.80%

LT Debt / Equity (Annual)0.07x

P/CF (TTM)29.77x

ROI (5Y Avg)-17.39%

LT Debt / Equity (Quarterly)0.09x

EPS Basic Excl Extra (TTM)$-0.79

P/TBV (Quarterly)1.47x

P/B Ratio (Annual)0.97x

Inventory Turnover (TTM)2.18x

Pretax Margin (TTM)-8.82%

Book Value / Share (Annual)$10.33

Price vs S&P 500 (13W)-6.64%

Beta0.24x

P/FCF (Annual)44.17x

Revenue / Share (TTM)$8.59

ROE (TTM)-7.74%

52-Week Low$7.87

vGradeC

gGradeF

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 260.27est. -0.16

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.25

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
ANIKAnika Therapeutics Inc	C	F	B	$14.48
SYKStryker Corporation	C	C	C	$305.66
MMM3M Company	C	F	C	$153.76
BSXBoston Scientific Corp.	C	B	D	$48.55
MDLNMedline Inc. Class A common stock	C	D	D	$33.61
BDXBecton, Dickinson and Co.	B	C	C	$151.16
RMDResMed Inc.	C	B	C	$196.04
DXCMDexCom, Inc.	C	B	C	$72.86
WSTWest Pharmaceutical Services, Inc.	D	C	B	$314.50
SOLVSolventum Corporation	C	D	B	$81.01
PENPenumbra, Inc.	F	C	B	$320.53

About

Anika Therapeutics develops osteoarthritis pain management solutions using proprietary hyaluronic acid technology. The company's principal products—Orthovisc, Monovisc, and Cingal—are office-administered viscosupplement products marketed exclusively in the U.S. by Johnson & Johnson MedTech. Primary revenue is derived from the U.S. market, with additional contributions from OEM licensing and international operations.